Emilio Pizzichini

List of Publications by Year
in descending order

84	10,240	117625	60623
papers	citations	34 h-index	81 g-index

88	88	88	8632
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Consensus on mild asthma management: results of a modified Delphi study. Journal of Asthma, 2023, 60, 145-157.	1.7	7
2	Primary Care Management of Asthma Exacerbations or Attacks: Impact of the COVID-19 Pandemic. Advances in Therapy, 2022, 39, 1457-1473.	2.9	8
3	Body mass index, asthma, and respiratory symptoms: a population-based study. Jornal Brasileiro De Pneumologia, 2020, 46, e20190006.	0.7	12
4	Prevalence and Characteristics of Asthmaâ€“Chronic Obstructive Pulmonary Disease Overlap in Routine Primary Care Practices. Annals of the American Thoracic Society, 2019, 16, 1143-1150.	3.2	32
5	A review of the burden and management of mild asthma in adults â€” Implications for clinical practice. Respiratory Medicine, 2019, 152, 97-104.	2.9	13
6	Prevalence of smoking and reasons for continuing to smoke: a population-based study. Jornal Brasileiro De Pneumologia, 2019, 45, e20170080.	0.7	12
7	How does the GINA definition of control correlate with quality of life and sputum cellularity?. ERJ Open Research, 2019, 5, 00146-2018.	2.6	5
8	Cannabidiol reduces airway inflammation and fibrosis in experimental allergic asthma. European Journal of Pharmacology, 2019, 843, 251-259.	3.5	84
9	IL-5 Levels in Nasosorption and Sputosorption Correlate with Sputum Eosinophilia in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 240-243.	5.6	10
10	Translation and cultural adaptation of the Kingâ€™s Brief Interstitial Lung Disease health status questionnaire for use in Brazil. Jornal Brasileiro De Pneumologia, 2019, 45, e20180194.	0.7	1
11	Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR Â® Post-Hoc Analysis. Archivos De Bronconeumologia, 2018, 54, 140-148.	0.8	4
12	Rigor Is Needed When Making Comparative Analyses of Biologics in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1508-1510.	5.6	2
13	Extrafine Versus Fine Inhaled Corticosteroids in Relation to Asthma Control: A Systematic Review and Meta-Analysis of Observational Real-Life Studies. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 907-915.e7.	3.8	36
14	The patient profile of individuals with Alpha-1 antitrypsine gene mutations at a referral center in Brazil. Jornal Brasileiro De Pneumologia, 2018, 44, 383-389.	0.7	3
15	Evaluation of the preference, satisfaction and correct use of BreezhalerÂ® and RespimatÂ® inhalers in patients with chronic obstructive pulmonary disease â€“ INHALATOR study. Respiratory Medicine, 2018, 144, 61-67.	2.9	17
16	Rhinosinusitis symptoms, smoking and <scp>COPD</scp>: Prevalence and associations. Clinical Otolaryngology, 2018, 43, 1560-1565.	1.2	14
17	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1268-1278.	5.6	60
18	Is the COPD Assessment Test sensitive for differentiating COPD patients from active smokers and nonsmokers without lung function impairment? A population-based study. Jornal Brasileiro De Pneumologia, 2018, 44, 213-219.	0.7	10

#	Article	IF	Citations
19	Late Breaking Abstract - Revisiting interpretation of blood eosinophil counts (BECs): data from Brazil. , 2018, , .		0
20	Identifying Risk of Future Asthma Attacks Using UK Medical Record Data: A Respiratory Effectiveness Group Initiative. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 1015-1024.e8.	3.8	82
21	Blood eosinophil count and exacerbation risk in patients with COPD. European Respiratory Journal, 2017, 50, 1700761.	6.7	64
22	Cardiovascular risks in smokers treated with nicotine replacement therapy: a historical cohort study. Clinical Epidemiology, 2017, Volume 9, 231-243.	3.0	16
23	The Quebec Sleep Questionnaire on quality of life in patients with obstructive sleep apnea: translation into Portuguese and cross-cultural adaptation for use in Brazil. Jornal Brasileiro De Pneumologia, 2017, 43, 331-336.	0.7	4
24	Translation and cultural adaptation of a specific instrument for measuring asthma control and asthma status: the Asthma Control and Communication Instrument. Jornal Brasileiro De Pneumologia, 2017, 43, 264-269.	0.7	4
25	Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD. , 2017, , .		0
26	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β₂-agonist fixed-dose combination: RE²SPOND rationale and study design. International Journal of COPD, 2016, Volume 11, 1921-1928.	2.3	9
27	Characteristics of Patients With and Without COPD Exacerbations During the Tiotropium + Olodaterol TONADO Studies. Chest, 2016, 150, 858A.	0.8	2
28	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting Î²₂-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE²SPOND). A Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 559-567.	5.6	109
29	Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies. Respiratory Medicine, 2016, 117, 154-161.	2.9	124
30	The COPD Assessment Test: What Do We Know So Far?. Chest, 2016, 149, 413-425.	0.8	109
31	The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial. Journal of Allergy and Clinical Immunology: in Practice, 2016, 4, 104-113.e2.	3.8	86
32	Effects of comorbidities on the CAT score: A population-based study. , 2016, , .		0
33	Temporal trends in the prevalence of asthma and rhinoconjunctivitis in adolescents. Revista De Saude Publica, 2015, 49, .	1.7	5
34	Tiotropium and olodaterol fixed-dose combinationversusmono-components in COPD (GOLD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	6.7	294
35	Once-daily tiotropium RespimatÂ® 5ÂÎ¼g is an efficacious 24-hÂbronchodilator in adults with symptomatic asthma. Respiratory Medicine, 2015, 109, 329-338.	2.9	51
36	Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respiratory Medicine,the, 2015, 3, 367-376.	10.7	153

#	Article	IF	Citations
37	Pentraxin 3 sputum levels differ in patients with chronic obstructive pulmonary disease vs asthma. Annals of Allergy, Asthma and Immunology, 2015, 115, 485-489.	1.0	8
38	A summary of the new GINA strategy: a roadmap to asthma control. European Respiratory Journal, 2015, 46, 622-639.	6.7	636
39	The fixed-dose combination of tiotropium + olodaterol has a rapid onset of action in patients with COPD. , 2015, , .		0
40	Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations. , 2015, , .		0
41	Efficacy of tiotropium RespimatÂ® in adults with moderate asthma, by baseline LTRA use. , 2015, , .		0
42	Current role of anticholinergic drugs in the treatment of asthma: key messages for clinical practice. Polish Archives of Internal Medicine, 2015, 125, 859-866.	0.4	1
43	Effects of prednisone on eosinophilic bronchitis in asthma: a systematic review and meta-analysis,. Jornal Brasileiro De Pneumologia, 2014, 40, 552-563.	0.7	7
44	Leicester Cough Questionnaire: translation to Portuguese and cross-cultural adaptation for use in Brazil. Jornal Brasileiro De Pneumologia, 2014, 40, 213-221.	0.7	12
45	Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat® versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. International Journal of COPD, 2014, 9, 697.	2.3	88
46	Reliability of a rapid hematology stain for sputum cytology. Jornal Brasileiro De Pneumologia, 2014, 40, 250-258.	0.7	2
47	Complementing the Randomized Controlled Trial Evidence Base. Evolution Not Revolution. Annals of the American Thoracic Society, 2014, 11, S92-S98.	3.2	51
48	Tiotropium RespimatÂ® Add-On To Inhaled Corticosteroids Improves Lung Function In Patients With Symptomatic Mild Asthma: Results From A Phase III Trial. Journal of Allergy and Clinical Immunology, 2014, 133, AB4.	2.9	5
49	Benralizumab, an anti-interleukin 5 receptor Î± monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respiratory Medicine,the, 2014, 2, 879-890.	10.7	435
50	Tiotropium RespimatÂ® Add-On Therapy Reduces Airflow Obstruction In Patients With Symptomatic Moderate Asthma, Independent Of TH2 Inflammatory Status. Journal of Allergy and Clinical Immunology, 2014, 133, AB5.	2.9	5
51	Fluticasone/formoterol dry powder versus budesonide/formoterol in adults and adolescents with uncontrolled or partly controlled asthma. Respiratory Medicine, 2013, 107, 1330-1338.	2.9	14
52	Exacerbations of COPD and symptoms of gastroesophageal reflux: a systematic review and meta-analysis. Jornal Brasileiro De Pneumologia, 2013, 39, 259-271.	0.7	45
53	SNOT-22: psychometric properties and cross-cultural adaptation into the portuguese language spoken in Brazil. Brazilian Journal of Otorhinolaryngology, 2012, 78, 34-39.	1.0	23
54	AvaliaÃ§Ã£o da eficÃ¡cia e seguranÃ§a da associaÃ§Ã£o de budesonida e formoterol em dose fixa e cÃ¡psula Ãºnica no tratamento de asma nÃ£o controlada: ensaio clÃnico randomizado, duplo-cego, multicÃªntrico e controlado. Jornal Brasileiro De Pneumologia, 2012, 38, 431-437.	0.7	7

#	Article	IF	Citations
55	DoenÃ§a do refluxo gastroesofÃ¡gico e hiperresponsividade das vias aÃ©reas: coexistÃªncia alÃ©m da chance?. Jornal Brasileiro De Pneumologia, 2011, 37, 680-688.	0.7	7
56	Sputum induction in severe exacerbations of asthma: safety of a modified method. European Respiratory Journal, 2011, 38, 979-980.	6.7	7
57	ComposiÃ§Ã£o celular do escarro induzido em adultos saudÃ¡veis. Jornal Brasileiro De Pneumologia, 2011, 37, 348-353.	0.7	11
58	TraduÃ§Ã£o e adaptaÃ§Ã£o cultural do Asthma Control Scoring System (Sistema de Escore para Controle) Tj ETQq0 0 0 rgBT /Overlock	0.7	14
59	Monitoring sputum eosinophils in mucosal inflammation and remodelling: a pilot study. European Respiratory Journal, 2010, 35, 48-53.	6.7	18
60	Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia. New England Journal of Medicine, 2009, 360, 985-993.	27.0	1,260
61	Neutrophilic airway inflammation is a main feature of induced sputum in nonatopic asthmatic children. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1597-1601.	5.7	58
62	Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal, 2008, 31, 143-178.	6.7	2,510
63	DeterminaÃ§Ã£o do componente inflamatÃ³rio das doenÃ§as das vias aÃ©reas atravÃ©s do escarro induzido: utilizaÃ§Ã£o na prÃ¡tica clÃnica. Jornal Brasileiro De Pneumologia, 2008, 34, 913-921.	0.7	14
64	AvaliaÃ§Ã£o do questionÃ¡rio de controle da asma validado para uso no Brasil. Jornal Brasileiro De Pneumologia, 2008, 34, 756-763.	0.7	70
65	Safety of Sputum Induction in Moderate-to-Severe Smoking-Related Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2006, 3, 89-93.	1.6	17
66	Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma. Chest, 2006, 129, 246-256.	0.8	228
67	Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. European Respiratory Journal, 2006, 27, 964-971.	6.7	225
68	Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. European Respiratory Journal, 2006, 27, 483-494.	6.7	548
69	Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax, 2005, 60, 100-105.	5.6	36
70	Failure of montelukast to reduce sputum eosinophilia in high-dose corticosteroid-dependent asthma. European Respiratory Journal, 2005, 25, 41-46.	6.7	39
71	Monitoring response to treatment in asthma management: food for thought. Clinical and Experimental Allergy, 2004, 34, 1168-1177.	2.9	19
72	Effects of cysteinyl leukotrienes and leukotriene receptor antagonists on markers of inflammation. Journal of Allergy and Clinical Immunology, 2003, 111, S49-S61.	2.9	30

#	Article	IF	Citations
73	Airway inflammation in steroid-naÃ¯ve asthmatics: characteristics of induced sputum. Jornal De Pneumologia, 2003, 29, 188-195.	0.1	2
74	Nonasthmatic Chronic Cough: No Effect of Treatment with an Inhaled Corticosteriod in Patients without Sputum Eosinophilia. Canadian Respiratory Journal, 1999, 6, 323-330.	1.6	80
75	Asthma and Natural Colds. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1178-1184.	5.6	202
76	Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 924-930.	5.6	259
77	Induced Sputum in the Management of Asthma. Seminars in Respiratory and Critical Care Medicine, 1998, 19, 581-592.	2.1	8
78	Sputum Eosinophilia Predicts Benefit from Prednisone in Smokers with Chronic Obstructive Bronchitis. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1511-1517.	5.6	349
79	Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: A randomized, placebo controlled trial. Canadian Respiratory Journal, 1998, 5, 261-268.	1.6	55
80	Sputum in severe exacerbations of asthma: kinetics of inflammatory indices after prednisone treatment.. American Journal of Respiratory and Critical Care Medicine, 1997, 155, 1501-1508.	5.6	260
81	Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 308-317.	5.6	900
82	Airway eosinophilia in chronic bronchitis during exacerbations.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 1726-1727.	5.6	4
83	Spontaneous and induced sputum to measure indices of airway inflammation in asthma.. American Journal of Respiratory and Critical Care Medicine, 1996, 154, 866-869.	5.6	212
84	Mepolizumab para el tratamiento de asma grave eosinofÃ¼lica. Revista Alergia Mexico, 0, 67, .	0.1	3